Liquidia Co. (NASDAQ:LQDA) General Counsel Sells $193,109.54 in Stock

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 16,393 shares of the firm’s stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $193,109.54. Following the completion of the transaction, the general counsel now directly owns 573,478 shares in the company, valued at approximately $6,755,570.84. The trade was a 2.78 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Russell Schundler also recently made the following trade(s):

• On Monday, December 2nd, Russell Schundler sold 1,063 shares of Liquidia stock. The stock was sold at an average price of $11.51, for a total transaction of $12,235.13.

Liquidia Price Performance

Shares of NASDAQ LQDA opened at $12.14 on Thursday. The firm has a fifty day moving average price of $11.23 and a 200-day moving average price of $11.02. The stock has a market cap of $1.03 billion, a PE ratio of -7.45 and a beta of 0.23. Liquidia Co. has a 1 year low of $8.26 and a 1 year high of $16.99.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Wells Fargo & Company assumed coverage on shares of Liquidia in a research report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target on the stock. Lifesci Capital assumed coverage on shares of Liquidia in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price target on shares of Liquidia in a research report on Thursday, January 9th. Scotiabank initiated coverage on shares of Liquidia in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $29.00 price objective on shares of Liquidia in a research note on Thursday, November 14th. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $25.38.

Hedge Funds Weigh In On Liquidia

Institutional investors have recently bought and sold shares of the stock. Quest Partners LLC purchased a new position in Liquidia during the second quarter valued at $27,000. Clear Harbor Asset Management LLC purchased a new position in Liquidia during the third quarter valued at $100,000. Signaturefd LLC grew its stake in Liquidia by 38,400.0% during the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after acquiring an additional 9,984 shares in the last quarter. Ballentine Partners LLC purchased a new position in Liquidia during the third quarter valued at $110,000. Finally, Whitcomb & Hess Inc. grew its stake in Liquidia by 10.2% during the third quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock valued at $116,000 after acquiring an additional 1,074 shares in the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).